Introduction {#Sec1}
============

*SCN9A* gene encodes the voltage-gated sodium channel NaV1.7, one of the nine known α members of voltage-gated sodium (Nav) channels \[[@CR1]\]. It mainly expresses in dorsal root ganglion neurons, thus its mutations are mainly associated with pain disorders \[[@CR2]\]. However, more and more studies have shown that *SCN9A* mutations in patients are also associated with variable epilepsy phenotypes including febrile seizures (FS) \[[@CR3]\], GEFS+ \[[@CR4]\], and Dravet syndrome (DS) \[[@CR5]\] in recent years. *GABRG2* gene (γ-aminobutyric acid receptor subunit gene), *SCN1A* gene, and *GABRA1* gene are most frequently mentioned in GEFS+ \[[@CR6]--[@CR8]\], while the role of *SCN9A* gene in GEFS+ still remains unknown. Here, we report a novel previously unreported likely pathogenic *SCN9A* Y1958C heterozygous mutation with no *SCN1A* mutations in a Chinese family with GEFS+ and explore the possibility of *SCN9A* contributing to GEFS+.

Material and methods {#Sec2}
====================

Family recruitment {#Sec3}
------------------

A family with 10 living Han members across three generation participated in the study. All the subjects signed the informed consent. Clinical data were collected from all members.

Targeted exon capture and sequencing {#Sec4}
------------------------------------

After signing the consent, 2\~4-ml peripheral blood from the ten members were collected. Blood Genome Column Medium Extraction Kit (Kangweishiji, China) was used to extract genomic DNA from blood samples. Whole-exome enrichment was performed using IDT_xGEN, which targets 39Mb protein-coding region of the human genome and covers 51Mb of partial intron. High-throughput sequencing was performed by Illumina NOVASeq 6000 series sequencer; the sequencing process was performed by Beijing Chigene Translational Medicine Research Center.

Sequence alignment and variant calling {#Sec5}
--------------------------------------

All reads were mapped to the human reference sequence (hg 19) using BWA-MEM (version 0.7.12). Then, a genome analysis tool kit (GATK version 3.4.0) was used to refine the alignments by performing local indel realignment and subsequent base quality recalibration. Single-nucleotide variants (SNVs) and insertions/deletions (indels) were called with the haplotype caller of the GATK. The variant was compared against publicly available databases such as the 1000 Genomes Project and the Exome Aggregation Consortium database (ExAC). At last, protein damage analysis was conducted to qualitatively predict the probability of the results by SIFT, PolyPhen-2, and MutationTaster, and multispecies alignments were performed using Mega 7.0 to determine whether the affected amino acids were conserved.

Results {#Sec6}
=======

Case description {#Sec7}
----------------

The proband (IV1) is a 9-year-old boy with normal spontaneous vaginal delivery and development. He presented the first seizure at 1 year and 4 months when encountering a respiratory tract infection with a fever (41 °C). Since then, he experienced febrile seizures for 9 times in total. The eighth seizure occurred at the age of 4, and he did not have convulsions in the next 4 years. The seizure patterns of the first time to the eighth time were all presented as generalized tonic-clonic seizures (GTCS), while the patient showed GTCS and absences on the ninth seizure when he was 9 years old with a fever. All the seizures last for about 1--2 min and could remit spontaneously. No obvious abnormality was found on neurological examination and brain magnetic resonance imaging (MRI). One week later after the last seizuring, electroencephalogram monitoring showed atypical spike-and-slow waves in the right temporal regions during sleep. In the further pedigree investigation, the proband's father (III3) experienced febrile seizures at about 1 year old and one of the proband's aunts (III1) reported febrile seizures at the age of two (Fig. [1a](#Fig1){ref-type="fig"}). The seizure patterns were also described as GTCS. Their seizures remitted spontaneously at that time and have not recurred until now. The proband's grandmother (II4) and grandfather (II3) did not remember whether they had convulsions in their childhood. Besides, the family history of two dead family members (I1, I2) could not be obtained. The other family members denied seizure. None of them were treated with antiepileptic drugs for their seizures.Fig. 1**a** Family pedigree. The black arrow indicates the proband; the legend for the symbols is at the right top of the figure. **b** Identification of a heterozygous mutation c.5873A\>G (p.Y1958C) in the family members: proband (IV1), proband's father (III3), proband's aunt (III1), and proband's grandmother (II4). Additional Sanger sequencing results are given in Online Resource (Figs. [3](#Fig3){ref-type="supplementary-material"} and [4](#Fig4){ref-type="supplementary-material"}) The red arrow shows an A to G transition of nucleotide 5873

Genetic findings {#Sec8}
----------------

A novel heterozygous *SCN9A* mutation (c.5873A\>G) was detected in the proband (IV1), proband's father (III3), proband's aunt (III1), and proband's grandmother (II4) by using clinical whole-exome sequencing, and Sanger sequencing was used to validate it (Fig. [1b](#Fig1){ref-type="fig"}). No mutations in *SCN1A* were detected. This mutation (c.5873A\>G chr2:167055243 p.Y1958C) occurs in the population at a frequency of \< 0.5% in the ExAC database (<http://exac.broadinstitute.org/variant/2-167055243-T-C>) and has not been reported in previous study or presented in dbSNP (<http://evs.gs.washington.edu/EVS/>) and 1000 Genomes Project (<https://www.internationalgenome.org/>). Multiple sequence alignment was performed by using Mega 7.0 (<https://www.megasoftware.net/>), and residue Y1958 is highly conserved (Fig. [2](#Fig2){ref-type="fig"}). The results of three bioinformatics programs show that the novel mutation could damage the function of the protein (Table [1](#Tab1){ref-type="table"}). The pathogenicity of this variant is classified likely pathogenic, following the principle of standards and guidelines recommended by ACMG in recent publication \[[@CR9]\].Fig. 2Alignment of multiple *SCN9A* protein sequences across species. The Y1958C affected amino acid locates in the highly conserved amino acid region in different mammals (from Ensembl). Red column shows the Y1958C siteTable 1The prediction of the identified variant in *SCN9A*Gene namePositionTranscriptSubstitutionExACdbSNP ID1000GPolyphen2SIFTMutationTaster*SCN9A*chr2:167055243NM_002977c.5873A\>G/Y1958C0.0001NovelNovel0.99 (probably damaging)0.01 (damaging)0.999993 (disease-causing)*ExAC*, Exome Aggregation Consortium; *1000G*, 1000 genomes

Discussion {#Sec9}
==========

GEFS+ is a complex autosomal dominant disorder with conspicuous phenotypic heterogeneity \[[@CR10]\]. The first and second frequent phenotypes are febrile seizures, where generalized tonic-clonic seizures (GTCS) with fever occur between 3 months and 6 years, and febrile seizures plus (FS+), in which attacks with fever extend beyond 6 years or afebrile GTCS occur, respectively. The other phenotypes include FS/FS+ with absence, myoclonic, atonic, or focal seizures \[[@CR11]\]. In our study, the proband experienced FS and FS+ with absence while his father and aunt only had febrile seizures, probably due to the incomplete penetrance and/or the phenotypic heterogeneity. As for the proband's grandmother (II4), she did not remember whether convulsions had occurred in her childhood.

Several genes have been announced to be associated with GEFS+, in which *GABRG2*, *SCN1A*, and *GABRA1* account for the major part \[[@CR6]--[@CR8]\], while *SCN9A* is only reported in a few cases. A potentially pathogenic *SCN9A* variant, L266M (in exon 7), was discovered in one GEFS+ family \[[@CR5]\]. Cen et al. reported a small pedigree diagnosed as GEFS+ with a heterozygous mutation (Q10R) in *SCN9A* gene without *SCN1A* mutation \[[@CR4]\]. In 2019, a heterozygous mutation in the *SCN9A* gene, p.(Lys655Arg), in two sisters from a non-consanguineous family who presented GEFS+ was detected \[[@CR11]\]. Actually, *SCN9A* variant is often mentioned as a genetic modifier in *SCN1A* mutation-associated epilepsy. A heterozygous *SCN9A* mutation, p.N641Y, was found to be responsible for a large Utah family (K4425) suffering from FS and GEFS+, and the authors identified nine *SCN1A* mutations with six different *SCN9A* mutations in this study \[[@CR3]\]. However, the exact role of *SCN9A* mutations without *SCN1A* variants in GEFS+ has still remained left unclear. Thus, we hope to provide more evidence to illustrate that *SCN9A* has an important bearing on GEFS+ development in addition to these cases.

*SCN9A*, encoding sodium channel Nav1.7, contains 27 exons on chromosome 2q24.3 \[[@CR12]\]. Nav1.7 is composed of 1977 amino acids and is organized into 4 domains, each with 6 trans-membranes \[[@CR1]\]. In our study, a novel *SCN9A* heterozygous mutation (c.5873A\>G) causing a missense mutation (p.Y1958C) was discovered. Regrettably, the mutation didn't occur in the 4 and the exact cellular mechanism is unclear. However, the mutation in our study was located in highly conserved positions. The *SCN9A* N641Y mutation in FS proved to reduce thresholds to electrically induced seizures, and increase seizure susceptibility by targeted knock-in mouse model was also in highly conserved positions \[[@CR3]\]. So, we speculate that the *SCN9A* Y1958C mutation might also affect the selectivity of the ion channel. Besides, the bioinformatics programs also demonstrated that the novel mutation could damage the function of the protein. All the evidences confirmed that the *SCN9A* p.Y1958C mutation should be regarded as pathogenic mutation in this family.

This report further supports that *SCN9A* mutation without *SCN1A* mutations is associated with GEFS+ and expands the spectrum of *SCN9A* gene, but there are limitations in our study that should be addressed. Thus, the functional effect of the mutation should be further studied to strengthen our views.
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